Blessed to have an incredible clinic, lab team, and collaborators. This holiday season, we came together to paint our shared vision for the future: a colorful, beautiful, and healthy brain—free of metastasis. Grateful for this talented, passionate, and committed team making this

Kidney Cancer Highlights from ESMO 2025! @IKCCorg @myESMO #ESMO25 @OncoAlert @ONCOassist https://t.co/qhaiSgiSJ4

🚨 Breaking RCC update from Merck (Oct 28, 2025) Two back-to-back positive Phase 3 trials for belzutifan (WELIREG®) 👇 1️⃣ LITESPARK-022 – Adjuvant setting 📍 Pembrolizumab + Belzutifan vs Pembrolizumab alone ✅ Significant DFS improvement in resected clear-cell RCC after

Thank you to @OSUCCC_James brilient Urooncologist Dr. @eric_facs for arrenging this outstanding @KidneyCancer local meeting and let us to spend time with @Brutus_Buckeye as well and sharing our expertise. @ChristianRolfo @HasanovLab @KimrynRathmell @OSU_Urology @OhioStateMedOnc

Outstanding talk at @KidneyCancer local community talk from our @OSUCCC_James and @OhioStatePIIO raising star Dr. @HasanovLab (Elshad Hasanov) 🙏🎉👏 https://t.co/RhyCdqayTw @OhioStateMedOnc @OSU_Urology #KCA #KidneyCancer #OSUCCC #Oncology #Research #Collaboration #GUOnc

🕺🏻🥳🎉 !!WOW!! Brutus seriously knows how to jazz up a crowd! Thanks for bringing your energy to our #kidneycancer patient education event today! #GoBucks @OSUCCC_James @Brutus_Buckeye

Empowering You @KidneyCancer Patient Education Event: Inspiring and comprehensive morning session and panel discussion by @GEVaughan1 @eric_facs @fuatbcr @lingbin_meng @MartyMakary @shawndason @OSUWexMed @OSU_Urology Tremendous progress in the field, yet many important questions

Excited to join our @KidneyCancer for the upcoming local #KidneyCancer meeting! Connecting clinicians, patients, and researchers to advance #RCC care and #PrecisionOncology 💪 @OhioStateCancer @OSU_Urology @OhioStateMedOnc @HasanovLab

🚨 Registration closes soon! https://t.co/csnBVMCpMU Join the KCA and @OhioStateMedOnc next week — October 25 for a FREE #kidneycancer edu event. Hear directly from experts and connect with others who understand. Special thanks to @eric_facs @KimrynRathmell 🧡

Wonderful dinner with @eric_facs and our team! Great discussions and excitement for tomorrow’s patient event at @OSUCCC_James! https://t.co/hLB0bhkpai

So excited to welcome everyone today to @OSUCCC_James for a patient education symposium! We have an exciting group of speakers to lead our discussions on treatment, disease management, patient experiences, and so much more. Thank you @OhioState for your partnership!

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel

@ScottHaake @VUMCDiscoveries showing impressive objective responses for angiogenically selected patients w #kidneycancer on #OPTICRCC - had patients on this #DOD funded trial @utswcancer #ESMO25 #ESMOAmbassadors @OncoAlert @myESMO

Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews #ESMO25 #ESMOAmbassadors @OncoAlert

Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert

Up-lifting post-PD1 head-to-head by @OncHahn in a Ph.II trial! Len/Eve vs Cabo in metastatic ccRCC with PD-1 1L progression. PFS HR 0.51 (95% CI 0.29-0.89); p= 0.02. ORR 53% vs 39% (ctrl) p=0.17. #ESMO25 #RCC @myESMO @OncLive @OncoAlert @Annals_Oncology

Impressive and remarkable biomarker-driven 1L by @DrScottHaake in OPTIC RCC, Ph.II trial: RNAseq-guided nivolumab+cabozantinib for angiogenic cluster 1/2. ORR 71% (PR 71%, SD 29%, PD 0); 100% tumor shrinkage (n=21). Prospectively selected tissue-based rna biomarker to guide

🎯 adapting 1L treatment to mRNA Clusters in mRCC preliminary report of Angio Cluster 1-2 with Nivo-Cabo Excellent exploratory molecular-driven study!! 76% ORR without PD! @myESMO @OncoAlert @OncBrothers @urotoday @DrChoueiri @tompowles1 #ESMO25

PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the